Liminal BioSciences Inc. LMNL

Healthcare Biotechnology

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.

NDAQ:LMNL - Post by User

Liminal BioSciences Inc.

<< Previous

Bullboard Posts

Next >>

Post by Redtail2on Sep 28, 2019 1:33pm

232 Views

Post# 30173817

Either PLI was too greedy or 4050 didn't cut it.

Boehringer Ingelheim Gambles $2.62 Billion on Two Fibrotic Disease Deals

Quote:
South Korea-based Bridge Biotherapeutics licensed outits BB-877 to Germany-basedBoehringer Ingelheim for a total deal of about $1.75 billion. This is the second large deal for fibrotic diseases Boehringer Ingelheim inked since the beginning of the month.

Under the terms of the agreement, Boehringer Ingelheim is paying Bridge Bio$50.57 million up front and up to $1.25 billion in milestone payments. On top of that, Bridge Bio will be eligible for royalties on any subsequent marketed product.

BB-877 was originally discovered by LegoChem Biosciences. In 2017, LegoChem licensed the product to Bridge Bio. The compound is in a Phase I clinical trial in the U.S. It is being developed for fibrotic diseases like idiopathic pulmonary fibrosis (IPF) and non-alcoholic steatohepatitis (NASH). The initial development will be for IPF.

Quote:
Fibrotic diseases are of growing interest to Boehringer Ingelheim. On July 1, Boehringer Ingelheim signed a collaboration and license dealwith South Korea’s Yuhan Corporation to develop a first-in-class dual agonist for NASH and related liver diseases. Their focus will be on combining GLP-1 and FGF21 activity in one molecule.